How much does a box of Clofazimine soft capsules cost?

Clofazimine (Clofazimine) is an oral drug in soft capsule form, mainly used for the treatment ofleprosy and drug-resistant tuberculosis. It achieves bacteriostatic effects by interfering with the cell metabolism of mycobacteria and has a certain anti-inflammatory effect, helping to control inflammatory reactions. Therefore, clofazimine is included in some tuberculosis treatment regimens recommended by the World Health Organization (WHO) globally, and it plays an important role especially in drug-resistant cases.

In the domestic market, clofazimine is already on the market and has been included in the scope of medical insurance reimbursement. Patients can purchase it directly at regular hospital pharmacies. The common specifications are 50mg*10 tablets, and the price per box is about 500 yuan. Due to differences in medical insurance policies in different regions, the final out-of-pocket amount of patients may be different. The addition of medical insurance reimbursement has greatly reduced the financial burden of patients.

In overseas markets, clofazimine is also widely available, and relatively low-priced generics exist. For example, some foreign pharmaceutical manufacturers have launched clofazimine in 100mg*100 capsules, and the price per box is only about 400 yuan. These generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, providing more choices for patients with limited economic conditions.

In terms of purchasing channels, domestic patients mainly use hospital pharmacies to ensure that the sources of drugs are regular and safe. When purchasing drugs overseas, patients should obtain them through legal channels to avoid drug quality problems caused by non-compliant sources. With the popularity of generic drugs, the price system of clofazimine tends to be diversified so that patients with different economic conditions can obtain treatment.

In summary, clofazimine soft capsules, as an important drug in the treatment of tuberculosis and leprosy, have clear clinical application value, and their prices are gradually becoming more rational driven by medical insurance support and the launch of generic drugs. Whether purchasing drugs domestically or through overseas channels, patients can find suitable options to ensure the continuity and accessibility of long-term treatment.

Reference materials:https://www.novartis.com/our-products/pipeline/clofazimine